Skip to main content
Stephen Williamson, MD, Oncology, Kansas City, MO

StephenKWilliamsonMDRetired June 2021(he/him)

Oncology Kansas City, MO

Gastrointestinal Cancer, Thoracic Cancer

Professor Emeritus, Division of Oncology, Dept of Internal Medicine, University Kansas School of Medicine

Dr. Williamson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Williamson's full profile

Already have an account?

  • Office

    1216 W 71 Ter
    Kansas City, MO 64114

Education & Training

  • University of Kansas School of Medicine
    University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 1984 - 1986
  • University of Oklahoma School of Community Medicine (Tulsa)
    University of Oklahoma School of Community Medicine (Tulsa)Residency, Internal Medicine, 1979 - 1982
  • University of Kansas School of Medicine
    University of Kansas School of MedicineClass of 1979
  • Kansas Newman College
    Kansas Newman CollegeB.S., 1972 - 1976

Certifications & Licensure

  • KS State Medical License
    KS State Medical License 1982 - 2025
  • MO State Medical License
    MO State Medical License 1984 - 2025
  • OK State Medical License
    OK State Medical License 1980 - 1984
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • University of Kansas Top Doc Award Kansas University Hospital, 2005
  • Best Doctors in America 2005
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?  
    Chintala L, Vaka S, Baranda J, Williamson SK, Oncol Rev, 1/1/2011
  • Chemotherapy in Head and Neck Cancer: Clinical Predictors of Tolerance and Outcomes  
    Kubicek GJ, Kimler BF, Wang F, Reddy EK, Girod DA, Williamson SK, Am J Clin Oncol, 1/24/2010
  • Treatment of Gastric Cancer (Letter to editor)  
    Singh J, Williamson SK, Malani AK, NEJM, 1/1/2006
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • A Phase I Trial of Irinotecan (Iri) and Buparlisib (B) in Previously Treated Patients (PTS) with Metastatic Colorectal Cancer (mCRC).
    J.C. Baranda, G. Reed, S. Williamson, M. Stoltz, R. Perez, C. Mackay, R. Madan, J.Scott, A, Meeting 2014 European Society for Medical Oncology, 2014 European Society for Medical Oncology, 1/26/2014
  • Phase I clinical trial of the intraperitoneal (IP) administration of a novel nanoparticle formulation of paclitaxel (NTX).
    Williamson SK, Wick J, Chapman JA, Johnson G, Reed G, Schulz TK, Smith H, Weir S, Decedue CJ, Howell, J and Roby, K, Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, 1/31/2013
  • Docetaxel followed by temsirolimus suppresses mTOR pathway and can overcome PI3K / AKT over-activation mechanism of resistance in lung cancer cell line.
    Huang CH, Godachova A, Misra J, Holton E, Beaudoin C, Williamson, SK, Van Veldhuizen PJ, Annual Meeting of the American Association for Cancer Research, Washington, DC, 1/6/2013
  • Join now to see all

Lectures

  • Update on Hepatocelllular Carcinoma, an Oncologist's Perspective 
    University of Kansas Medical Center, Kansas City, KS - 1/1/2011
  • Update on AJCC Staging and use of EMR for staging 
    University of Kansas Medical Center, Kansas City, KS - 1/1/2010
  • Best of Oncology 2008 
    University of Kansas Medical Center, Kansas City, KS - 1/1/2008
  • Join now to see all

Press Mentions

  • Thermo Fisher Scientific Q2 Revenues Soar 10 Percent, Driven by Pandemic Demand
    Thermo Fisher Scientific Q2 Revenues Soar 10 Percent, Driven by Pandemic DemandJuly 22nd, 2020

Professional Memberships